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The cerebral microvasculature is important for maintaining brain homeostasis. This is
achieved via the blood-brain barrier (BBB), composed of endothelial cells with specialized
tight junctions, astrocytes, and a basement membrane (BM). Prominent components of
the BM extracellular matrix (ECM) include fibronectin, laminin, collagen IV, and perlecan,
all of which regulate cellular processes via signal transduction through various cell mem-
brane bound ECM receptors. Expression and proteolysis of these ECM components can be
rapidly altered during pathological states of the central nervous system. In particular, prote-
olysis of perlecan, a heparan sulfate proteoglycan, occurs within hours following ischemia
induced by experimental stroke. Proteolysis of ECM components following stroke results
in the degradation of the BM and further disruption of the BBB. While it is clear that such
proteolysis has negative consequences for the BBB, we propose that it also may lead to
generation of ECM protein fragments, including the C-terminal domain V (DV) of perlecan,
that potentially have a positive influence on other aspects of CNS health. Indeed, perlecan
DV has been shown to be persistently generated after stroke and beneficial as a neuro-
protective molecule and promoter of post-stroke brain repair. This mini-review will discuss
beneficial roles of perlecan protein fragment generation within the brain during stroke.
Keywords: perlecan, blood-brain barrier, vascular basementmembrane, extracellularmatrix, domainV, stroke, brain
INTRODUCTION
A number of neurological diseases such as multiple sclerosis,
Alzheimer’s disease, and stroke have been associated with dysfunc-
tion of the blood-brain barrier (BBB; Zlokovic, 2008; Yang and
Rosenberg, 2011; D’Aversa et al., 2012). The BBB consists of sev-
eral layers of protection between the blood and brain parenchyma,
endothelial cells with specialized junctions and transporters, the
vascular basement membrane (BM) composed of extracellular
matrix (ECM), and the astrocyte end-feet. While numerous studies
have focused on examining the role of tight junctions and trans-
port mechanisms such as ABC transporters (e.g., P-glycoprotein)
within the endothelial cells, much less is known about the role of
the vascular BM during brain injury and disease.
Prominent ECM components of the vascular BM include
fibronectin, laminin, collagen IV, and perlecan, all of which reg-
ulate cellular processes and homo- and heterotypic intercellular
signaling via interaction with integrins and other ECM recep-
tors (del Zoppo and Milner, 2006; Baeten and Akassoglou, 2011).
During development these substances play a critical role in the
assembly and stability of BMs, which are located throughout the
body and especially important for the proper development of the
heart, cartilage, and brain (Yurchenco and Schittny,1990; Arikawa-
Hirasawa et al., 1999; Costell et al., 1999; Giros et al., 2007). During
pathological conditions of the central nervous system (CNS), the
expression and proteolysis of these ECM components is altered
due to an increase in the activity of proteases including matrix
metalloproteinases (MMPs), cathepsins, and others (Fukuda et al.,
2004). In particular, the heparan sulfate proteoglycan perlecan
is proteolytically cleaved within hours following ischemic stroke
(Lee et al., 2011). Such proteolysis results in the degradation of
the vascular BM and further disruption and dysfunction of the
BBB.
While it is clear that such proteolysis has some negative con-
sequences for the BBB, we propose that it also may lead to the
generation of ECM protein fragments, including the C-terminal
domain V (DV) of perlecan, that potentially have a positive influ-
ence on other aspects of CNS health. Indeed, increased production
of perlecan DV is observed within the ischemic core and penumbra
following experimental stroke (Lee et al., 2011), suggesting it may
play a role in the brain’s response to stroke. In this mini-review we
will discuss the role of perlecan within the brain and the possible
beneficial role of perlecan protein fragment generation following
stroke.
WHAT IS THE MATRIX?
The BBB exists to maintain brain homeostasis and normal neu-
ronal function. The major structures which characterize the BBB
are: (1) tight junctions and adherens junctions between adjacent
microvessel endothelial cells, which impart a high transendothe-
lial electrical resistance and low paracellular permeability; (2)
intact vascular BM; (3) pericytes; (4) astrocyte end-feet (Figure 1).
Recent data suggest that the endothelial cell barrier properties
are only partly explained by tight junction proteins. Pericytes are
important for capillary stabilization and maturation of endothe-
lial cell contacts and astrocyte adhesion is required to regulate
the quality of the barrier (Bolton et al., 1998; Wolburg and
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FIGURE 1 | Schematic representation of the blood-brain barrier (BBB).
The BBB consists of interendothelial cell tight junctions and adherens
junctions, the extracellular matrix components of the basement membrane,
pericytes and astrocyte end-feet. The basement membrane extracellular
matrix (ECM) components hold endothelial cells and astrocytes in close
proximity and contribute to the permeability and stability of the BBB. ECM
components include laminin, collagen IV, fibronectin, and perlecan which
bind to and signal through integrin (α and β) and dystroglycan (α and β)
receptors located on both endothelial cells and astrocytes. Perlecan, and
potentially other ECM components of the BBB, are processed into smaller
biologically active fragments upon BBB injury. We hypothesize that these
fragments, in turn, might have beneficial effects on brain injury recovery.
Figure adapted from Huber et al. (2001) and del Zoppo and Milner (2006).
Lippoldt, 2002; Willis et al., 2004; Dore-Duffy, 2008; Kamouchi
et al., 2012). Importantly, stability of the endothelial cell-astrocyte
configuration requires an intact vascular BM (Willis et al., 2004).
Basement membranes are sheet-like cell-adherent extracellu-
lar matrices that contribute to tissue organization, stability, and
differentiation (Yurchenco and Patton, 2009). The vascular BM
surrounds vascular endothelia and is composed of the ECM
components laminin, collagen type IV, fibronectin, and perlecan
(Figure 1). Proper positioning of astrocyte end-feet to the ablu-
minal endothelial surface occurs via the cross-linked network of
these ECM components and integrin and dystroglycan cell surface
receptors (Willis et al., 2004). While laminin appears to be the pri-
mary ECM component required for BM assembly, perlecan plays
a critical role in BM maintenance and stability (Arikawa-Hirasawa
et al., 1999; Costell et al., 1999). A lack of perlecan in vivo has been
shown to lead to disrupted BMs and even lethality due to develop-
mental defects (George et al., 1993; Arikawa-Hirasawa et al., 1999;
Poschl et al., 2004).
PERLECAN
Perlecan (>400 kDa) is a heparan sulfate proteoglycan which con-
tains a multi-domain protein core and three glycosaminoglycan
chains at its N-terminus. Its five distinct domains (Figure 2) are
FIGURE 2 | Schematic diagram of human perlecan. Perlecan is made up
of five domains and contains various predicted and experimentally
determined proteolytic (proteases as labeled) cleavage sites. aSaini and Bix
(2012); bGonzalez et al. (2005). Adapted from Farach-Carson and Carson
(2007) and Whitelock et al. (2008).
known to interact with a wide range of biological molecules,
including growth factors and other ECM components, allowing
it to mediate cell signaling events controlling migration, prolif-
eration, and differentiation (Whitelock et al., 2008). Perlecan has
also long been speculated to serve as an extracellular depot or
reservoir for growth factors, potentially released upon ECM dis-
ruption (Bix and Iozzo, 2008). Developmental in vivo studies have
shown that perlecan is of particular importance during cardiovas-
cular, cartilaginous, and neural development. Perlecan-deficient
mice demonstrate a complex series of phenotypes which are not
confined to one tissue or organ system. Embryos lacking perlecan
showed severe chondrodysplasia, life-threatening malformations
of the heart outflow tract, as well as impaired telencephalic devel-
opment (Handler et al., 1997; Costell et al., 1999; Ford-Perriss
et al., 2003). Most of the mice survive the very early stages of
development, but approximately half die around embryonic day
10.5 (E10.5) because of either malformations of the heart or fail-
ure of the nervous system to develop. Those that are born die soon
thereafter because of respiratory failure likely due to major skeletal
abnormalities present in the ribs.
Studies have shown that perlecan-deficient mice exhibit normal
BM formation, but with time BM regions exposed to increased
mechanical stress, such as the expanding brain ventricles, deterio-
rate. This decrease in brain BM integrity leads to neuronal ectopias
and exencephaly (Costell et al., 1999). In addition, Giros et al.
determined that perlecan influences the size of the ventral and
cortical telencephalic structures, as both of these were reduced in
perlecan-deficient mice. Giros et al. (2007) speculated that this
deficit may be due to insufficient recruitment and/or signaling by
the morphogen Sonic hedgehog (SHH) in the basal lamina of the
floor plate. High levels of perlecan protein and mRNA expres-
sion have also been observed in the developing vascular system,
including the cerebral microvasculature (Handler et al., 1997).
The process of blood vessel formation is thought to involve acti-
vation of growth factors (e.g., FGF and TGFβ), differentiation of
smooth muscle cells, inhibition of endothelial cell proliferation,
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and activation of matrix production (Folkman and Shing, 1992).
As mentioned above, perlecan is thought to be an important reg-
ulator of growth factor signaling and could modify the behavior
of replicative cells by controlling the amount of various growth
factors involved in vascular morphogenesis (Handler et al., 1997).
Growth factors which bind to perlecan include vascular
endothelial growth factor (VEGF), platelet-derived growth factor
(PDGF), transforming growth factor (TGFβ), and in particular
the fibroblast growth factor (FGF) family (for review see White-
lock et al., 2008), known regulators of neovascularization. Deguchi
et al. (2002) demonstrated that perlecan mediates FGF internaliza-
tion at the endothelial cells of the BBB and suggest that it may also
be an important carrier of FGF secreted from astrocytes. Perlecan,
therefore, plays an important role in BBB function via growth fac-
tor regulation, as FGF is suggested to be one of the soluble factors
necessary for maintaining BBB integrity.
Effects of perlecan on the endothelial cells of the cerebral
microvasculature also occur via the integrin and dystroglycan
families of matrix adhesion receptors. These receptors regulate
cell behavior by transducing extracellular stimuli to intracellu-
lar signals, and they form a physical link between the intracellular
cytoskeleton and the ECM. They are expressed on endothelial cells
and astrocytes and evidence suggests that their expression is per-
turbed during pathological states of the CNS, including cerebral
ischemia. Perlecan (Domain V) is known to bind to α2β1 and
α5β1 integrins and to α-dystroglycan (Bix et al., 2004; Ahsan et al.,
2011; Wright et al., 2012). Interestingly, when endothelial cells
were cultured on single ECM component substrates perlecan not
only increased expression of α5β1 integrin, but it did so more than
collagen IV and fibronectin (Milner et al., 2008b). This data indi-
cate that perlecan is also able to regulate BBB function by way of
receptor expression.
PERLECAN PROTEOLYSIS
As mentioned above, perlecan is important for normal neural
development and proper functioning of the BBB. What happens
to perlecan following brain injury or disease? Is perlecan sim-
ply degraded? Perlecan expression has been shown to decrease
43–63% within a few hours following middle cerebral artery occlu-
sion as measured by perlecan immunohistochemistry (Fukuda
et al., 2004). Interestingly, however, it is quite likely that this study
employed multiple perlecan monoclonal antibodies that collec-
tively could not detect all five perlecan protein domains. For
example, the clone A7L6 antibody used in the study is specific
for perlecan domain IV. Along this line of reasoning, we pro-
pose that perlecan, rather than simply being degraded after brain
injury/disease, is being processed into potentially beneficial pro-
tein fragments. Such fragments may not have been detected in
the Fukuda et al. study due to incomplete immunogenic cover-
age of the perlecan protein core. However, the Fukuda et al. study
importantly determined that following cerebral ischemia perlecan
is the most sensitive ECM component (compared to collagen or
laminin) to proteolysis in the ischemic core (Fukuda et al., 2004).
Indeed, in our own studies, the C-terminal fragment of perlecan,
DV, is endogenously and persistently increased following stroke
in mice and rats (Lee et al., 2011), sheep, non-human primates,
and humans (unpublished data from Bix Lab). Additionally, in
rats and mice, the C-terminal fragment of DV, laminin-like globu-
lar domain 3 (LG3), is increased (i.e., proteolytically cleaved from
full length perlecan) in ischemic tissue following oxygen-glucose
deprivation (Saini et al., 2011). DV and LG3 are proteolytically
cleaved via cathepsins and BMP-1/Tolloid-like MMPs (Gonzalez
et al., 2005), which are also upregulated following stroke.
Using oxygen-glucose deprivation (OGD), an in vitro model
system reproducing these primary stimuli that injure cells dur-
ing stroke, our group showed that neurons and pericytes, but not
astrocytes, increase their release of LG3. Interestingly however,
upon reperfusion all three of these cell types show increased LG3
when stimulated by brief durations of OGD. This is in contrast to
prolonged durations of OGD where neurons, pericytes, and brain
endothelial cells show decreased LG3 (Saini et al., 2011). Specifi-
cally, the source of this increased LG3 following OGD appears to be
the result of increased perlecan synthesis and secretion. Addition-
ally, increased cathepsin-L, which appears to be important for LG3
cleavage under normal conditions, and cathepsin-B,which appears
to be important for LG3 cleavage following OGD, increase LG3.
It is also important to note that the inflammatory mediator inter-
leukin (IL)-1α also increased cathepsin-B and LG3 levels (Saini and
Bix, 2012). Collectively, perlecan and its DV and LG3 fragments
are increased following stroke, which likely involves multiple cell
types.
The findings of increased perlecan and its fragments following
stroke led us to hypothesize that these molecules may play a role
in stroke outcome. Initially, we demonstrated that strokes in mice
that expressed 10% of total normal perlecan levels (perlecan hypo-
morphs) suffered significantly larger infarcts (and more severe
functional deficits) than their wildtype littermates, suggesting that
perlecan, and potentially by extension, DV/LG3, play a role in
the brain’s response to transient ischemia. We then demonstrated
robust benefits of administering exogenous human recombinant
DV following experimental stroke in rodents. Importantly, most
of these benefits were replicated in two different species – rats and
mice, using two different stroke models – a tandem ipsilateral com-
mon carotid and middle cerebral arteries occlusion (CCA/MCAo)
model and the endothelin (ET)-1 injection model. Benefits of DV
administration following stroke include: (1) neuroprotection, (2)
angiogenesis, (3) rescue of stroke-affected motor function, and (4)
modulation of astrocyte activity and reduction of glial scar.
(1) Neuroprotection: When administered by intraperitoneal (i.p.)
injection beginning 24 h after injury and then every-other day
following, DV decreased ischemic lesion size (as measured
by TTC and H&E staining) and reduced immunoreactivity
of TUNEL and Caspase-3 cleavage (markers of apoptosis; Lee
et al., 2011). Furthermore, LG3 was neuroprotective in vitro to
fetal cortical neurons exposed to OGD, when compared to PBS
treated controls, as evident by a 300% viability increase and
decreased immunohistochemical staining of Caspase-3 (Saini
et al., 2011). Interestingly, DV and LG3 were also neuroprotec-
tive to Amyloid-β mediated toxicity (believed to play a role in
Alzheimer’s disease), via α2- and αv-β1 integrins, in human
cortical neurons (Wright et al., 2012). Collectively, these
findings indicate that perlecan DV/LG3 is neuroprotective
following stroke, OGD, and Amyloid-β stressors, suggesting
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that perlecan and its fragments may also be neuroprotective
to other CNS diseases and insults as well.
(2) Angiogenesis: Post-stroke exogenously administered DV
induced the secretion of VEGF from brain endothelial cells,
as evidenced by ELISA and Western blot. This release in
VEGF occurred following DV association with its endothelial
cell α5β1 receptor resulting in the formation of new blood
vessels, as evidenced by immunohistochemistry. Although
α5β1 integrin is largely absent in the brain’s microvascula-
ture after development, it is re-expressed following stroke and
is increased in brain endothelial cells in direct response to per-
lecan, thereby facilitating an angiogenic cascade (Milner et al.,
2008a). Mechanistically, DV appears to activate PI3K-Akt,
MEK-ERK, eIF4E, c-Jun, and HIF-1α downstream from its
α5β1 integrin receptor to induce VEGF synthesis and release
from brain endothelial cells (Clarke et al., submitted manu-
script). Importantly, this DV-induced increase in VEGF and
angiogenesis does not cause further disruption of the BBB
(Lee et al., 2011). The mechanisms responsible for this appar-
ent paradox – VEGF not causing further disruption of the
BBB – have not yet been fully elucidated but likely involve
indirect action by another cell type, potentially astrocytes.
(3) Rescue of stroke-affected motor function: In both wildtype and
perlecan hypomorph animals, DV restored (to pre-stroke
levels) stroke-affected motor function as measured by the
vibrissae-elicited paw placement test and the cylinder test.
This functional rescue was stable 2 weeks after injury (Lee
et al., 2011).
(4) Modulation of astrocyte activity and reduction of glial scar :
Exogenous DV administration decreases astrogliosis in vitro,
and the post-stroke secretion of glial scar proteins neurocan
and phosphacan in vivo (Al-Ahmad et al., 2011). This
reduction of glial scar is a significant finding as glial scar
can be a physical and chemical barrier to neurorepair fol-
lowing stroke. We have also shown that DV has direct effects
on astrocytes and influences their activity in vitro (Al-Ahmad
et al., 2011). For example, DV inhibits the proliferation and
promotes the adhesion, migration, stellation morphology, and
secretion of NGF from astrocytes.
Importantly, DV-induced neuroprotection and rescue of motor
function were also observed following a permanent photothrom-
bosis model of stroke conducted in a laboratory distinct from our
own (Clarkson et al., submitted manuscript). In this model, DV
administration was effective when treatment was initiated 6 h, but
not 8 or 12 h, following injury. This earlier therapeutic window
may be accounted for by the faster evolution of infarct size in
the photothrombotic model compared to CCA/MCAo and ET-1
models.
In summary, we suggest that perlecan, and potentially other
ECM components of the BBB, is not simply degraded after
stroke, but is actively processed, resulting in the endogenous
generation of DV and LG3. DV and LG3, in turn, appear to
be important to the brain’s response to stroke inasmuch as
their deficiency results in worsened stroke outcomes. Further-
more, when DV is administered after stroke, it provides vari-
ous benefits including neuroprotection, angiogenesis, rescue of
stroke-affected motor function, and reduction of astrogliosis
and glial scar. Therefore, in conditions involving BBB dysfunc-
tion, we suggest that more attention be given to the bioac-
tive fragments of the ECM that are generated, as the ECM is
not simply degraded into inactive molecules. Ultimately, fur-
ther investigation may identify other biologically significant
BBB ECM fragments, expanding a relatively unexplored venue
of BBB research, and potentially leading to novel CNS thera-
pies.
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